The Penisula Health Technology Commissioning Group (PHTCG) has come to a decision on the use of Rituximab for severe ANCA Associated Vasculitis. Rituximab may be offered to patients who have received a Cyclophosphamide-base reigmen for induction of remission and have a major relapse or persistently active disease.
Informed consent must be obtained from the patient for this unlicensed use.
John Mills was asked to be part of the consultation process.
He reported his experiences with bladder cancer and how much it must be costing the NHS, the bladder cancer was brought on as a result of the repeated use of Cylophos. The carcinoma resulted in 3 operations and 3 short stays in hospital as well as 3 monthly checks using the "willy cam". (Cystoscopy)
John likes to think his report on his experiences had some influence on their final decision.